ATNM - Actinium Pharmaceuticals, Inc.
| Previous Close | 0.3049 |
| Open | 0.3000 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.2900 - 0.3050 |
| 52 Week Range | 0.2580 - 0.8650 |
| Volume | 785,322 |
| Avg. Volume | 1,435,553 |
| Market Cap | 48.14M |
| Beta (3Y Monthly) | 3.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.55 |
- PR Newswire•6 days ago
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
NEW YORK, May 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago. The data to be presented at ASCO is a new analysis from the first 25% of patients enrolled in the SIERRA trial highlighting that by day 3 after Iomab-B administration, patients had a 98% median reduction in peripheral blasts and 100% reduction in blasts by day 8.
- PR Newswire•15 days ago
Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
NEW YORK, May 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Niva Almaula, Ph.D. as Chief Business Officer, effective immediately. Dr. Almaula joins Actinium with significant experience in the targeted radiotherapy field, having most recently worked as Head, Business Development at Advanced Accelerator Applications, Inc., a nuclear medicine company acquired by Novartis for $3.9 billion in January 2018.
- PR Newswire•last month
Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
NEW YORK, April 18, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the pricing of an underwritten public offering of 42,860,000 shares of its common stock at a combined public offering price of $0.385 per share of common stock. The Company also announced the pricing of warrants to purchase up to 42,860,000 shares of common stock at an exercise price of $0.50 per share and with a term of 5 years commencing on the date of issuance. The offering is expected to close on or about April 23, 2019, subject to the satisfaction of customary closing conditions.
- PR Newswire•last month
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEW YORK, April 17, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Actinium intends to use the net proceeds from the sale of the common stock and warrants to fund its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate Iomab-B and progress Phase 1 trials from its refocused CD33 program to the proof of concept stage.
- PR Newswire•last month
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
NEW YORK, April 8, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 – 4, 2019 in Ottawa, Canada. Two oral and four poster presentations related to Actinium's AWE or Antibody Warhead Enabling technology platform and clinical programs were featured at the symposium while Actinium's Chief Scientific Officer, Dr. Dale Ludwig, participated in a panel titled, "The Renaissance of Radio Pharmaceuticals – A Commercial Perspective". Actinium has extensive experience with targeted alpha therapy including clinical data in over 100 patients from four clinical trials and extensive intellectual property, know-how and trade secrets related to Ac-225 or Actinium-225 applications and manufacturing.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
- Zacks•2 months ago
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
- PR Newswire•2 months ago
Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
- Studies observed increase in double-stranded DNA breaks and reduction in MCL-1 levels in cell lines resistant to venetoclax following Actimab exposure - Combination of Actimab-A and venetoclax resulted ...
- Zacks•2 months ago
What Makes Actinium (ATNM) a New Buy Stock
Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- PR Newswire•2 months ago
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
NEW YORK, March 29, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the second module of its previously announced research and option agreement with Astellas Pharma Inc. and that the third module has been initiated. In this collaboration, Actinium is utilizing its Antibody Warhead Enabling (AWE) technology platform to conjugate and label select targeting agents owned by Astellas with the potent alpha-particle emitting payload Actinium-225 (Ac-225) and conducting preclinical research that is being funded by Astellas.
- PR Newswire•2 months ago
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
- Two oral presentations, four poster presentations and panel participation will highlight Actinium's AWE technology platform, clinical programs, next-generation ARC's and the commercial renaissance of ...
- PR Newswire•2 months ago
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
NEW YORK, March 20, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that preclinical data from the novel combination of its CD33 ARC or Antibody Radiation-Conjugate Actimab-A (lintzumab-Ac-225) with venetoclax has been accepted for poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting 2019. The data to be presented builds on research by Actinium that demonstrated a synergy between Actimab-A and venetoclax, which resulted in greater cancer cell killing.
- PR Newswire•2 months ago
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs. In this role, Dr. Gokhale will be responsible for developing and implementing a comprehensive clinical regulatory strategy across Actinium's portfolio of ARC or Antibody Radiation-Conjugate product candidates for targeted conditioning.
- PR Newswire•2 months ago
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) reported its financial results for the fourth quarter and year ended December 31, 2018 as well as provided corporate and operational updates on clinical trials, research and development, recent hires, and intellectual property. Iomab-B is an ARC or Antibody Radiation-Conjugate that targets CD45, an antigen expressed on leukemia, lymphoma and immune cells, and delivers Iodine-131 that kills targeted cells via linear energy transfer.
- PR Newswire•2 months ago
Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that the rejuvenation of R&D activity has bolstered its patent portfolio to a total of 111 issued and pending patents in the U.S. and internationally, which is up from the 75 reported previously.
- PR Newswire•2 months ago
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
- Presentation scheduled for 1:35 pm ET on Wednesday, March 20th NEW YORK , March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") ...
- Simply Wall St.•2 months ago
What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?
A look at the shareholders of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusualRead More...
- ACCESSWIRE•3 months ago
4 Healthcare Stocks Looking To Kick Off A Strong Week
CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / The future success of the healthcare stock market will be determined by whether companies in the industry are aptly prepared to meet the growing demands for better healthcare. Medical professionals are now advocating for legislation in favor of legalizing marijuana because of the list of health benefits afforded to those who use medicinal cannabis. TSX: ACB), and Actinium Pharmaceuticals Inc (NYSE American: ATNM) represent four healthcare companies focused on improving the quality of life for their patients.
- PR Newswire•3 months ago
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was reported in a late breaking oral presentation at the 2019 Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR (TCT Meetings) that was held on February 20th – 24th. Dr. Sergio Giralt, Chief, Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center presented the late breaking oral presentation.
- PR Newswire•3 months ago
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that it reported data from its Iomab-ACT program in a poster presentation at the 2019 Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR (TCT Meetings). This program has the potential of providing a superior means of conditioning that could displace or replace chemotherapy based conditioning regimens such as Flu/Cy or Fludarabine and Cyclophosphamide that are used as the standard of practice today. The ARC underpinning the Iomab-ACT program is a lower dose version of Actinium's Iomab-B, which is in a pivotal Phase 3 trial for conditioning prior to a bone marrow transplant.
- GlobeNewswire•3 months ago
Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
- Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy NEW YORK , Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, ...
- PR Newswire•3 months ago
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced that it has further expanded the intellectual property portfolio for the technology underpinning its Iomab-ACT program. The Iomab-ACT program is being developed for lymphodepletion, which is also referred to as conditioning, prior to administration of CAR-T based therapies. Due to the targeted nature of the ARC or Antibody Radiation-Conjugate technology, the Iomab-ACT program could provide a superior means of conditioning that could displace or replace chemotherapy based conditioning regimens such as Flu/Cy or Fludarabine and Cyclophosphamide that are used as the standard of practice today.
- PR Newswire•3 months ago
Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that its novel Phase 1/2 combination trial of Actimab-A and venetoclax has been initiated. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center will serve as Principal Investigator for this study. The Phase 1/2 combination trial will enroll patients with relapsed or refractory AML or Acute Myeloid Leukemia that have been previously treated with venetoclax and patients that have never received venetoclax.
- PR Newswire•4 months ago
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin
NEW YORK, Feb. 4, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") announced today that the Medical College of Wisconsin (MCW) has started dosing patients in the second cohort of its novel trial of Actimab-A in combination with CLAG-M in patients with relapsed or refractory AML or Acute Myeloid Leukemia. This trial is evaluating the impact that the addition of targeted internalized radiation via Actimab-A to the salvage chemotherapy regimen CLAG-M will have on safety and tolerability, response rates, rates of BMT or bone marrow transplant, PFS or progression-free survival, and OS or overall survival.
